Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18271
Country/Region: Vietnam
Year: 2017
Main Partner: Ho Chi Minh Department of Health
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $2,243,541 Additional Pipeline Funding: $10,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $77,072
Care: TB/HIV (HVTB) $114,901
Care: Pediatric Care and Support (PDCS) $36,415
Laboratory Infrastructure (HLAB) $25,000
Strategic Information (HVSI) $120,000
Health Systems Strengthening (OHSS) $50,000
Testing: HIV Testing and Counseling (HVCT) $360,250
Sexual Prevention: Other Sexual Prevention (HVOP) $372,438
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $30,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $65,000
Treatment: Adult Treatment (HTXS) $949,636
Treatment: Pediatric Treatment (PDTX) $42,829
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 3,305
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 19,813
HTS_TST Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative 2018 868
HTS_TST Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative 2018 2,231
HTS_TST Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative 2018 2,000
HTS_TST Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative 2018 6,070
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative 2018 3,372
HTS_TST Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative 2018 7,163
HTS_TST Sum of Test Result disaggregates 2018 206
HTS_TST Sum of Test Result disaggregates 2018 1,208
HTS_TST_POS By Test Result: Positive 2018 206
HTS_TST_POS By Test Result: Positive 2018 1,208
HTS_TST_POS Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive 2018 33
HTS_TST_POS Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive 2018 173
HTS_TST_POS Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive 2018 91
HTS_TST_POS Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive 2018 439
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive 2018 120
HTS_TST_POS Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive 2018 558
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 1,810
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 100
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 1,120
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 953
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 7,570
KP_PREV By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 404
KP_PREV By key population type: Men who have sex with men and are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 72
KP_PREV By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 2,422
KP_PREV By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 427
KP_PREV By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 20
KP_PREV By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 128
KP_PREV By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 4
KP_PREV By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 22
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2018 1,553
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2018 13,499
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 509
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 18
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 34
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 1
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 447
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 17
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 22
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 6
PP_PREV Age/sex: 15-19 Female 2018 8
PP_PREV Age/sex: 15-19 Female 2018 75
PP_PREV Age/sex: 15-19 Male 2018 4
PP_PREV Age/sex: 15-19 Male 2018 21
PP_PREV Age/sex: 20-24 Female 2018 44
PP_PREV Age/sex: 20-24 Female 2018 369
PP_PREV Age/sex: 20-24 Male 2018 16
PP_PREV Age/sex: 20-24 Male 2018 157
PP_PREV Age/sex: 25-49 Female 2018 228
PP_PREV Age/sex: 25-49 Female 2018 2,010
PP_PREV Age/sex: 25-49 Male 2018 100
PP_PREV Age/sex: 25-49 Male 2018 868
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2018 400
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2018 3,500
PP_PREV Sum of Age/Sex disaggregates 2018 400
PP_PREV Sum of Age/Sex disaggregates 2018 3,500
TB_PREV By Age/Sex (Numerator): <15, Female 2018 11
TB_PREV By Age/Sex (Numerator): <15, Female 2018 2
TB_PREV By Age/Sex (Numerator): <15, Male 2018 12
TB_PREV By Age/Sex (Numerator): <15, Male 2018 2
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 25
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 184
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 45
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 426
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 93
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 614
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 116
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 767
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 14
TB_PREV_den By Age/Sex (Denominator): <15, Female 2018 2
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 14
TB_PREV_den By Age/Sex (Denominator): <15, Male 2018 2
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 30
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 228
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 58
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 535
TX_CURR Aggregated Age/Sex: <15 Female 2018 418
TX_CURR Aggregated Age/Sex: <15 Female 2018 22
TX_CURR Aggregated Age/Sex: <15 Male 2018 434
TX_CURR Aggregated Age/Sex: <15 Male 2018 27
TX_CURR Aggregated Age/Sex: 15+ Female 2018 641
TX_CURR Aggregated Age/Sex: 15+ Female 2018 2,889
TX_CURR Aggregated Age/Sex: 15+ Male 2018 1,171
TX_CURR Aggregated Age/Sex: 15+ Male 2018 6,622
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 2,664
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 9,560
TX_CURR Sum of Aggregated Age/Sex <15 2018 852
TX_CURR Sum of Aggregated Age/Sex <15 2018 49
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 1,812
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 9,511
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 2,664
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 9,560
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 17
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 2
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 18
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 2
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 38
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 287
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 72
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 667
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 145
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 958
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 145
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 958
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 1,728
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 7,648
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 1,608
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 7,113
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 302
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 16
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 314
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 20
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 364
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 2,149
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 628
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 4,928
TX_PVLS Numerator: Indication: Routine 2018 1,608
TX_PVLS Numerator: Indication: Routine 2018 7,113
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 324
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 17
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 337
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 21
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 392
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 2,312
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 675
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 5,298
TX_PVLS_den Denominator: Indication: Routine 2018 1,728
TX_PVLS_den Denominator: Indication: Routine 2018 7,648
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 35
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 2
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 37
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 3
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 90
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 308
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 165
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 718
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 327
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 1,031
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 371
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 1,171
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 40
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 2
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 41
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 3
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 104
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 351
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 186
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 815
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 2,532
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 9,083
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 88
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 319
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2018 13
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 14
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2018 1
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 20
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 97
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 41
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 221
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 398
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 21
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 413
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 26
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Female 2018 609
TX_TB_den Denominator: By Aggregated Age/Sex: 15+, Male 2018 1,112
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 2,746
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 6,290
Cross Cutting Budget Categories and Known Amounts Total: $10,000
Key Populations: MSM and TG $10,000
Collection and use of strategic information
Monitoring and evaluation of MSM/TG programs